The preliminary results of the ongoing trials demonstrate that anti-SLAMF7 CAR-Ts exhibit a significantly enhanced potency against MM cells compared to the anti-SLAMF7 antibody elotuzumab (ELO) [53]. Here, SLAMF7 is linked to Miyoshi myopathy.